deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01951326

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)

A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease

Sponsor: RedHill Biopharma Limited

Interventions Placebo RHB-104
Updated 24 times since 2017 Last updated: Nov 29, 2020 Started: Sep 30, 2013 Primary completion: May 31, 2018 Completion: Aug 31, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Crohn's Disease and is currently completed. RedHill Biopharma Limited leads this study, which shows 24 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Apr 2019 · 5 months · monthly snapshot~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

24 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

Show 19 earlier versions
  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Aug 2020 — Nov 2020 [monthly]

    Completed PHASE3

  4. Jul 2020 — Aug 2020 [monthly]

    Completed PHASE3

  5. Jun 2020 — Jul 2020 [monthly]

    Completed PHASE3

  6. Feb 2020 — Jun 2020 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  7. Apr 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Nov 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  10. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  13. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  14. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  15. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  16. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  17. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  18. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  19. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RedHill Biopharma Limited
Data source: RedHill Biopharma Limited

For direct contact, visit the study record on ClinicalTrials.gov .